Dianthus Therapeutics, Inc. Common Stock (DNTH) is a publicly traded Healthcare sector company. As of May 21, 2026, DNTH trades at $88.72 with a market cap of $4.57B and a P/E ratio of -20.90. DNTH moved +3.53% today. Year to date, DNTH is +140.50%; over the trailing twelve months it is +364.26%. Its 52-week range spans $13.37 to $96.50. Analyst consensus is strong buy with an average price target of $122.57. Rallies surfaces DNTH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Dianthus Secures Orphan Status, Hits Early CIDP Go and Raises $719M: Dianthus secured FDA Orphan Drug Designation for claseprubart in myasthenia gravis and reached an early GO decision in its Phase 3 CAPTIVATE CIDP trial after achieving 20 responders with fewer than 40 participants. The company raised $719 million in an equity offering, boosting cash to $1.2 billion and extending runway into 2030.
| Metric | Value |
|---|---|
| Price | $88.72 |
| Market Cap | $4.57B |
| P/E Ratio | -20.90 |
| EPS | $-4.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $96.50 |
| 52-Week Low | $13.37 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.34M |
| Net Income | $-173.66M |
| Gross Margin | 0.00% |
15 analysts cover DNTH: 0 strong buy, 15 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $122.57.